Estrella Immunopharma Inc. Common Stock (ESLA)
Stock · NASDAQ · Health Care
$0.705as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$0.729913
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About ESLA
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Website
- www.estrellabio.com/
Fundamentals
- 1-day range
- $0.64$0.755
- Market cap
- $30.12M
- P/E (trailing)
- —
- P/E (forward)
- -2.20
- EPS (trailing)
- $-0.35
- Dividend yield
- —
- Beta
- 0.91
- Avg. volume
- 40.1K
52-week range
$0.6781$3.15
Forecasts
1 analyst ratings
Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$12
+1602.1%
Median
$12
+1602.1%
Low
$12
+1602.1%
Estrella Immunopharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ESLAEstrella Immunopharma Inc. Common Stock$0.705▼ 2.10%Market cap $30.12MP/E —$0.6781$3.15
- ALGSAligos Therapeutics Inc. Common Stock$6.93▼ 1.98%Market cap $28.47MP/E —$3.98$13.69
- ELUTElutia Inc. Class A Common Stock$0.885▲ 0.57%Market cap $38.32MP/E 0.75$0.5$2.4
- DYAIDyadic International Inc. Common Stock$0.6207▼ 3.02%Market cap $38.63MP/E —$0.6197$1.6
- JSPRJasper Therapeutics Inc. Common Stock$0.6782▼ 2.98%Market cap $16.98MP/E —$0.3151$2.96
- TVGNTevogen Inc. Common Stock$6.89▲ 2.07%Market cap $45.04MP/E —$3.64$49.5
- PASGPassage Bio Inc. Common Stock$4.52▲ 4.39%Market cap $14.40MP/E —$3.29$20
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ESLA Estrella Immunopharma Inc. Common Stock | $30.12M | — | $0.705 | ▼ 2.10% | $0.6781$3.15 |
| ALGS Aligos Therapeutics Inc. Common Stock | $28.47M | — | $6.93 | ▼ 1.98% | $3.98$13.69 |
| ELUT Elutia Inc. Class A Common Stock | $38.32M | 0.75 | $0.885 | ▲ 0.57% | $0.5$2.4 |
| DYAI Dyadic International Inc. Common Stock | $38.63M | — | $0.6207 | ▼ 3.02% | $0.6197$1.6 |
| JSPR Jasper Therapeutics Inc. Common Stock | $16.98M | — | $0.6782 | ▼ 2.98% | $0.3151$2.96 |
| TVGN Tevogen Inc. Common Stock | $45.04M | — | $6.89 | ▲ 2.07% | $3.64$49.5 |
| PASG Passage Bio Inc. Common Stock | $14.40M | — | $4.52 | ▲ 4.39% | $3.29$20 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga · 8/5/2026
- Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaYahoo · 8/3/2026
- Estrella Immunopharma Activates Third Clinical Site For Ongoing STARLIGHT-1 Phase I/II Clinical Trial Evaluating EB103, CD19-Redirected ARTEMIS T-Cell Therapy, In Patients With R/R B-Cell Non-Hodgkin’s LymphomaBenzinga · 8/3/2026
Insider Activity
Insider Actions →Acquired
200.0K
Disposed
0
- Liu Cheng · August 25, 2026 · Option Exercise100.0K @ $0.815
- Xu Jiandong · August 18, 2026 · Option Exercise100.0K @ $0.815
Institutional Ownership
March 31, 2026
- Total shares held
- 5.11M
- Total value held
- $5.42M
- Institutional holders
- 15
Top holders this quarter
- Unknown4.10M
- Unknown382.5K
- Unknown264.4K
- Unknown157.5K
- Unknown62.8K
- Unknown43.3K
- Unknown39.9K
- Unknown19.6K
- Unknown16.9K
- Unknown15.1K
See the full, filterable feed with live charts on the MarketWall dashboard.